PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

UK Kidney Association Guideline Sets Anticoagulation Framework for AF in Advanced CKD and Dialysis

UKKA atrial fibrillation anticoagulation guidelineUK Kidney Associationadvanced CKDdialysisDOACsapixabanwarfarinleft atrial appendage occlusion Nephrology

Background Information

Managing AF in CKD patients is challenging due to bleeding risks.

Patients with advanced chronic kidney disease (CKD) are at high risk for both thromboembolic events and bleeding when managing atrial fibrillation (AF). New UK Kidney Association guidelines provide best-practice guidance for anticoagulation in CKD patients with AF, addressing the use of direct oral anticoagulants (DOACs) and non-anticoagulation options. The guidelines clarify decision-making for anticoagulation in this challenging population, though limitations exist due to the exclusion of patients with advanced CKD from major trials. New guidelines guide anticoagulation decisions in advanced CKD patients with AF.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Parker K, Power A, Buka R, Davies M, Gauci MA, Hancock A, Hartemink J, Mitchell A, Thomas H, Tsang JY, Tseng I, Turley A, Lip GYH, guideline authors

Citation: Parker K, Power A, Buka R, et al. Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK kidney association clinical practice guideline. BMC nephrology. 2026;27(1). doi:10.1186/s12882-026-05270-9

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.